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A growing number of studies indicate that 3-alpha reduced neurosteroids are remarkable
analgesics in various pain states. This is the case for allopregnanolone (AP), one of
the most potent endogenous positive allosteric modulators of GABAA receptor function.
From the pioneering work of Hans Selye, who described the sedative properties of
steroids, synthetic compounds resembling the progesterone metabolite AP have been
developed. If some of them have been used as anesthetics, it seems difficult to propose
them as a therapeutic option for pain since they display several adverse side effects
such as sedation, amnesia and functional tolerance. An alternative strategy, chosen
by few laboratories around the world, is aimed at stimulating the local production
of 3-alpha reduced neurosteroids in order to limit these well-known side effects.
This pharmacological approach has the advantage of targeting specific structures, fully
equipped with the necessary biosynthetic enzymatic machinery, where neurosteroids
already act as endogenous pain modulators. The various pharmacological trials which
attempted to treat pain symptoms by stimulating the production of 3-alpha reduced
neurosteroids are reviewed here, as well as novel neurotransmitter systems possibly
regulating their endogenous production.
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INTRODUCTION
In 1941, Selye reported that intraperitoneal injections of high
doses of progesterone produce anesthesia in the rat (Selye, 1941).
Several years later, this led to the development of steroidal
anesthetics (Child et al., 1971). Of particular interest are the
3α-reduced steroid compounds, such as alphaxalone, which dis-
play potent anesthetic properties. Indeed, they were found to
selectively act as positive allosteric modulators of the inhibitory
functions of GABAA receptors (GABAARs), expressed either at
extrasynaptic (Harrison and Simmonds, 1984) or synaptic sites
(Poisbeau et al., 1997; Cooper et al., 1999). After two decades
of research, two steroid binding sites on GABAARs have been
identified (Hosie et al., 2006). Modulation of GABAAR function
is observed after binding of a 3α-reduced steroid in a cavity
formed by the α-subunit transmembrane domains. A direct
activation of the receptor-channel is also observed at a higher
concentration if the binding is effective at interfacial residues
between α and β subunits. Interestingly, recent experiments
strongly suggest that these binding sites are reached by steroids
via lateral mobility in the cell membrane, and that they only
affect GABAAR function when accessing the intracellular part
of the channel (Akk et al., 2005). This observation may help
understanding the possible occlusion of steroid action when
the receptor is submitted to intracellular phosphorylation by
protein kinase C (Harney et al., 2003; Vergnano et al., 2007).
Many other receptor-channels were found to be modulated by
steroids (Schlichter et al., 2006) but, in most cases, this phys-
iological action was only observed at micromolar concentra-
tions. Without fully excluding elevated levels of steroids within
specific neuronal microdomains, such concentrations are unlikely
to occur in the central nervous system (CNS; Schumacher et al.,
2003).
It is interesting to note at this stage that neuroactive steroids
can be synthesized at the periphery (i.e., by gonads and adrenal
glands), but also by neural cells in the nervous system. This
discovery led Baulieu and collaborators to propose the term
“neurosteroids” for neuroactive steroids produced by neural cells
independently of the endocrine steroidogenic glands (Baulieu and
Robel, 1990). In the brain, similarly to any steroid-synthesizing
tissues, a mitochondrial protein complex called TSPO is necessary
to initiate the synthesis of neuroactive steroids (Rupprecht et al.,
2010). TSPO facilitates the translocation of cholesterol from the
outer to the inner mitochondrial membrane, where the P450
side-chain cleavage enzyme is located. The intramitochondrial
transport of cholesterol is considered as a rate-limiting step for
neurosteroidogenesis. Of course, this complex metabolic step can
Frontiers in Cellular Neuroscience www.frontiersin.org June 2014 | Volume 8 | Article 174 | 1
Poisbeau et al. Allopregnanolone: an endogenous analgesic
be bypassed if peripheral steroid hormones access the brain, as
they easily cross the blood-brain barrier. In this case, circulating
steroid hormones (i.e., progesterone, deoxycorticosterone, testos-
terone) may serve as precursors for neurosteroidogenic enzymes
synthesizing GABAAR active steroids (Figure 1A).
The purpose of this topical review is to illustrate the cur-
rent analgesic strategies aimed at stimulating the production of
endogenous neurosteroid analgesics in animal models. Two major
aspects will be covered: (i) the recent attempts to use TSPO
agonists for the production of steroid analgesics; and (ii) the iden-
tification of endogenous signaling pathways which may regulate
neurosteroidogenesis and could be targeted in the near future for
therapeutic purposes.
WHAT ARE THE ENDOGENOUS STEROID ANALGESICS?
LESSONS FROM EXOGENOUSLY-ADMINISTERED STEROIDS
AND CURRENT HYPOTHESIS FOR SEX-SPECIFIC PAIN
ISSUES
Since the early reports of Selye, several groups have characterized
the analgesic efficacy of steroid hormones, when administered
systemically, into cavities of the CNS (intracerebroventricular,
i.c.v. or intrathecally) or directly into rodent brain structures.
These observations also raised critical issues linked to the well-
known sex-specific differences in pain responses (Greenspan
et al., 2007). From many experiments, it is clear that the admin-
istration of testosterone or progesterone to rodents induces
antinociception and analgesia (Kavaliers and Wiebe, 1987; Frye
and Duncan, 1994; Pednekar and Mulgaonker, 1995). Conversely,
low levels of theses hormones, after gonadectomy for example, are
associated with low nociceptive thresholds and pain hypersensi-
tivity. Experimental evidences have also shown that the effects of
testosterone and progesterone are mediated by their neuroactive
metabolites, since analgesia is never observed in mice deficient for
5α-reductase (Frye et al., 2002, 2004). We recently contributed
to this field by showing that the analgesic action of AP (3α-
hydroxy-5α-pregnan-20-one or 3α,5α-tetrahydroprogesterone) is
mediated by a direct allosteric positive modulation of GABAARs
in the spinal cord of rats displaying mechanical or thermal pain
symptoms (Charlet et al., 2008). Coming back to the endocrine
control of nociception by steroid hormones, it is interesting to
note that the duration of miniature GABAAR-mediated synaptic
currents in the spinal cord is submitted to large variations dur-
ing the female reproductive cycle (Figure 1B). We found these
currents to be significantly longer in duration while recording
from layer II spinal neurons of adult females during proestrus
(i.e., during the progesterone surge) compared to those recorded
in late estrus when circulating progesterone is low (mean decay
time constant in proestrus: 31.9 ± 3.3 ms, n = 10 vs. estrus:
16.8 ± 2.9, n = 14; two-tailed unpaired Student’s t-test, p <
0.001). Interestingly, glycinergic synapses during proestrus are
also converted into mixed glycine/GABAergic synapses. Together,
this led to an increased inhibitory control of layer II neurons
processing pain informations and in a reduction in the intensity
of pain symptoms, as previously demonstrated (Keller et al.,
2001, 2004; Inquimbert et al., 2008). Since layer II neurons are
fully equipped to synthesize AP from progesterone, it is likely
that progesterone reaching the spinal cord is converted to AP,
which potentiates the affinity of GABAARs for GABA at indi-
vidual synapses. This is fully in agreement with previous studies
indicating that female pain thresholds are controlled by the levels
of circulating gonadal steroids and, among them, progesterone
(Greenspan et al., 2007).
Based on these observations, several groups around the world,
including ours, have demonstrated the efficacy of administering
AP for alleviating pain symptoms (Kavaliers and Wiebe, 1987;
Frye and Duncan, 1994; Charlet et al., 2008; Meyer et al., 2008,
2011). This strategy, although very efficient in the short-term,
has major disadvantages since a systemic/oral administration of
AP-like steroids may generates negative side effects such as seda-
tion, fatigue, nausea and functional tolerance. If the treatment is
stopped or not properly controlled, it may also give rise to severe
withdrawal symptoms (Smith, 2001, 2002; Gulinello and Smith,
2003). It remains that AP has an interesting therapeutic potential
as pain killer in pathological pain states. Interestingly, endogenous
concentrations of AP are affected in various neuropathologies
including peripheral neuropathies (Melcangi et al., 2011). For
example, AP concentrations were found particularly low in the
distal portion of an injured sciatic nerve and correlated with
low expression levels of 5α-reductase (Roglio et al., 2008). In
apparent contradiction, 5α-reductase activity is high in the spinal
cord of rats exhibiting inflammatory pain symptoms (Poisbeau
et al., 2005). Since pain responses are exacerbated after inhibition
of 5α-reductase activity, this demonstrates that the synthesis of
AP-like steroids may limit pain symptoms. More recently, 3α-
HSOR expression and activity were also found to be elevated in
the spinal cord dorsal horns of neuropathic rats (Meyer et al.,
2008).
Taken together, these results show that AP-like compounds,
exogenously administered, are particularly efficient for limiting
pain symptoms. Several reports also indicate that they may exert a
general neuroprotective action. In peripheral nerves, in the spinal
cord and in various supraspinal structures, there is a significant
production of these putative pain killers (Caruso et al., 2013).
A straightforward strategy would be to stimulate this widespread
endogenous analgesic system. This has, at least, one major advan-
tage: to limit the possible unwanted side effects seen when AP is
given per os or via the general circulation.
STIMULATING THE SYNTHESIS OF ALLOPREGNANOLONE
FOR PRODUCING ANALGESIA
The mitochondrial TSPO complex is the main molecular tar-
get exploited so far to efficiently stimulate neurosteroidogenesis
(Rupprecht et al., 2009). Many TSPO ligands have been devel-
oped and tested successfully as neurotherapeutics in experimental
models of painful diabetic and chemotherapy-induced neuropa-
thy (Bordet et al., 2008; Aouad et al., 2009), mononeuropa-
thy after chronic nerve constriction (Aouad et al., 2014a) and
monoarthritis induced by persistent knee inflammation (Aouad
et al., 2014b).
When we first attempted to stimulate the production of 3α-
reduced neurosteroids in the spinal cord, we incubated the slices
in the presence of the classical benzodiazepine diazepam and
of flumazenil, a silent antagonist of the benzodiazepine site on
GABAARs (Keller et al., 2004). This favored the binding of
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FIGURE 1 | (A) Simplified diagram summarizing the key steps of
neurosteroidogenesis from cholesterol precursors to 3α-reduced
neurosteroids (3α-androstanediol, 3α-THDOC, 3α-THP). These end-chain
metabolites are potent positive allosteric modulators of GABAARs after
binding to specific binding sites. Abbreviations: DOC,
deoxycorticosterone; DHDOC, 5α-dihydrodeoxycorticosterone; THDOC,
3α,5α-tetrahydrodeoxycorticosterone; DHP, 5alpha-dihydroprogesterone;
THP, 3α,5α-tetrahydroprogesterone (= AP); 5α-R, 5α-reductase; 5α-HSOR,
3α-hydroxysteroid oxydoreductase; P450scc, P450 side-chain cleavage
enzyme. (B) Top graphs summarize the global changes in blood estradiol
(blue) and progesterone (red) during different phases of the reproductive
cycle in female rats. Patch clamp traces below are representative of
inhibitory postsynaptic currents mediated by GABAARs in the spinal cord
of female Sprague-Dawley rats during estrus and proestrus (i.e., when
progesterone levels are low and high, respectively). Adapted from
Keller (2002).
diazepam on the mitochondrial TSPO and promoted the local
synthesis of AP-like neurosteroids. Indeed, GABAAR-mediated
synaptic currents were longer in duration, suggesting an increased
affinity of the receptor-channel for GABA. We further confirmed
3α-reduced neurosteroids to be responsible for this increased
spinal inhibition by blocking this effect with the TSPO inhibitor
PK11195 or the 3α-reductase inhibitor finasteride (Keller et al.,
2004). Apart from characterizing the key role of neurosteroids
in the developmental maturation of inhibitory spinal synapses,
the increased spinal inhibition was found to be responsible for
the limitation of thermal hyperalgesia in a rodent model of
inflammatory pain (Poisbeau et al., 2005). Beside GABAARs,
Frontiers in Cellular Neuroscience www.frontiersin.org June 2014 | Volume 8 | Article 174 | 3
Poisbeau et al. Allopregnanolone: an endogenous analgesic
note here that 3α-reduced neurosteroids may also inhibit T-type
calcium channels to produce analgesia as previously published
(Pathirathna et al., 2005). As mentioned earlier, it is difficult to use
exogenous administration of AP-like steroids or benzodiazepines
in vivo (see however Brinton, 2013). We thus tried to use a TSPO
ligand to achieve similar goals. We choose etifoxine (EFX) because
its properties had been already characterized on primary culture
of hypothalamic neurons and on freshly-dissociated neonatal
spinal neurons (Schlichter et al., 2000).
EFX (2-ethylamino-6-chloro-4-méthyl-4-phényl-4H-3,1-ben
zoxazine chlorhydrate) is prescribed in several countries as a non-
benzodiazepine anxiolytic (Servant et al., 1998; Nguyen et al.,
2006). At an efficient anxiolytic dose in human, it can be used
safely (e.g., no functional tolerance and no physical dependence
after treatment cessation) and displays limited adverse side effects
on cognitive functions and vigilance (Micallef et al., 2001). EFX
preferentially binds and modulates GABAARs containing β2/3
subunits, at a site close to the chloride channel and distinct from
that of benzodiazepines (Verleye et al., 1999, 2002; Hamon et al.,
2003). Beside this direct effect on GABAARs, EFX also binds
to TSPO with an apparent affinity of about 20 µM (Verleye
et al., 2005). If rats are sacrificed 30 min after a single injection
of EFX of the reference anxiolytic dose of 50 mg/kg i.p., the
plasmatic and brain concentrations of AP are increased by 2–
4 times (Verleye et al., 2005). An increase in AP was also seen
in EFX-treated male rats in the absence of gonads and adrenal
glands. Because AP is a potent allosteric positive modulator of
GABAARs, this molecular mechanisms is referred to as “indirect”
on GABAAR function. While studying the functional consequence
of EFX on hypothalamic primary cultures, we found that it
strongly affected the tonic inhibition mediated by extrasynaptic
receptors (Schlichter et al., 2000). More recently, we also found
that the indirect neurosteroid-mediated effect of EFX prolonged
GABAAR-mediated synaptic currents in layer II neurons of the
spinal cord (Aouad et al., 2014b).
Spinal inhibition, when reduced, gives rise to pathological
pain symptoms and it is then crucial to maintain or to increase
inhibitory controls to limit pain states. Because EFX may theoret-
ically increase inhibitory controls mediated by GABAARs, directly
or indirectly, we choose to administer EFX (50 mg/kg, five daily
injections i.p.) to animals exhibiting generalized neuropathic pain
symptoms after chemotherapy with vincristine (VCR) sulphate,
oxaliplatin or paclitaxel (Figure 2). The very low values for
mechanical thresholds after chemotherapy were consistent with
the presence of mechanical allodynia in all rat groups and models.
Normal mechanical thresholds were, however, restored after EFX
treatment, except if rats were pre-treated with an inhibitor of 3α-
HSOR (depo-provera = medroxyprogesterone acetate) as shown
in Figure 2 (orange bar). Interestingly, EFX analgesia persisted
even if the gonads and adrenals were removed (Figure 2, right
graph). This strongly suggests that EFX analgesia is almost exclu-
sively carried by the production of AP-like neurosteroids.
TSPO EXPRESSION, POSSIBLE CELL COOPERATION AND
SIGNALING MECHANISMS
The above results, combined with recently published data (Aouad
et al., 2010, 2014a,b), raise several critical questions regarding the
TSPO-mediated mode of action of EFX. First, EFX clearly displays
anti-allodynic/hyperalgesic properties but does not modify basal
nociceptive thresholds of symptom-free animals (or body parts;
e.g., sham-operated paw or contralateral territories to the lesion
site). The second important observation is related to the efficacy
of the effect, which not only fully alleviates pain symptoms, but
also prevents their re-appearance after cessation of the treatment.
In the model of rat sciatic nerve constriction, we failed to observe
any pain symptoms for about 90 days after the treatment (Aouad
et al., 2014a). As highlighted in a Pain editorial, there is thus an
urgent need for a clinical trial testing the translational interest
of this molecule in human pain pathologies (Zeilhofer, 2009).
In addition, the molecular and cellular mechanisms recruited
by EFX need to be identified and will require complementary
experiments. Beside the sensori-discriminative component of
pain responses, the real action of EFX on the affectivo-emotional
component need, for example, to be clarified. This will require
studying the supraspinal action of EFX in brain structures pro-
cessing nociceptive informations and setting the emotional pain
responses.
Of particular interest are the neuroregenerative and neuro-
protective effects of the molecule described in a model of sciatic
nerve lesion (Girard et al., 2008) or of diabetic neuropathy (Giatti
et al., 2009). After cryolesion of the rat sciatic nerve, EFX therapy
not only accelerated but also improved the quality of axonal
regeneration and functional recovery (Girard et al., 2008). This
was an important observation, as poor regeneration of axons
may result in chronic neuropathic pain. Once again, little is
known regarding the molecular mechanisms recruited to protect
and promote peripheral nerve recovery, and there is so far little
information concerning the cellular targets of EFX. Within the
peripheral nervous system, TSPO is upregulated in macrophages,
Schwann cells and dorsal root ganglia (DRG) sensory neurons in
response to injury and disease (Karchewski et al., 2004; Rupprecht
et al., 2010). A synergistic cooperation between these different
cell types could be of utmost importance for neuroregenerative
processes as well as pain-related neuropathologies.
Indeed, TSPO protein levels are upregulated in the ipsilateral
spinal cord in rats displaying inflammatory pain symptoms after
knee injection of complete Freund’s adjuvant (Hernstadt et al.,
2009). A recent study also reports an increase in the number
of TSPO binding sites (e.g., using [3H] PK11195, a well known
TSPO ligand) in the spinal cord of rats, exhibiting neuropathic
and osteoarthritic pain symptoms (Miller et al., 2013). According
to this study, the increase in [3H] PK11195 binding in the spinal
cord seems to occur in microglial cells. TSPO is strongly expressed
in activated microglia (Benavides et al., 1983; Moynagh et al.,
1991; Itzhak et al., 1993; Park et al., 1996; Karchewski et al.,
2004; Hernstadt et al., 2009; Varga et al., 2009). Microglial TSPO
requires a particular attention due the key role of this cell type
in the initiation and maintenance of chronic pain states (Tsuda
et al., 2005). The recruitment of TSPO signaling is also of interest
while dealing with pain models associated with lesions during
the process of recovery. For example, regulation of the expres-
sion of TSPO and of their endogenous ligands have been well
studied during rat sciatic nerve degeneration and regeneration
(Rupprecht et al., 2010). After nerve freezing lesion or chronic
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FIGURE 2 | Histogram on the left illustrates the mechanical
nociceptive threshold measured with a calibrated forceps in control
(black bar, treated with the vehicles) and after treatment with
oxaliplatin (green bars; 2 mg/kg, injection i.p. twice-weekly for
four-and-a-half consecutive weeks), paclitaxel (blue bars; 2 mg/kg
i.p. on four alternate days: day 1,3,5,7), vincristine sulphate (pink
bars; 0.1 mg/kg, five daily injections i.p.). Note that all rats exhibited
low mechanical thresholds after chemotherapy (Tukey, p < 0.001; n = 6–8
rats per groups) but normal thresholds were restored after five daily
injections with etifoxine (EFX, 50 mg/kg i.p.). EFX analgesia was abolished
in animals pre-treated for 1 week before VCR with depo-provera (orange
bar; inhibitor of 3α-HSOR, five daily injections of 5 mg/kg s.c.). Graph on
the right illustrates the time course of mechanical threshold in
gonadectomized/adrenalectomized (GDX/ADX) rats, submitted to VCR
chemotherapy (or saline) and treated for their mechanical allodynia with
EFX (or vehicle). Note that EFX analgesia persisted even in the absence of
peripheral source of steroids. Abbreviations: EFX: etifoxine, Sal: saline,
VCR: vincristine, Veh: vehicle. Adapted from Aouad et al. (2010).
denervation, a clear over-expression of TSPO and octadecaneu-
ropeptide (ODN) is observed in Schwann cells and macrophages,
suggesting their crucial role during regenerative processes (Lacor
et al., 1996). Axonal injury-dependent induction of TSPO has
been also observed in small-diameter adult rat primary sensory
neurons (Karchewski et al., 2004).
ENDOGENOUS CONTROL OF ALLOPREGNANOLONE
SYNTHESIS AND ANALGESIC FUNCTION
Many endogenous ligands of TSPO have been identified and are
described in detail in a recent review (Rupprecht et al., 2010).
If their binding characteristics and neurosteroidogenic activities
are well understood, very little is known regarding their role in
brain functions and pathologies (Rupprecht et al., 2010). Choles-
terol and porphyrins are important endogenous ligands of TSPO
and display nanomolar to micromolar affinities, respectively.
Endozepines, discovered at the end of the 80 s, are peptidergic
ligands capable of displacing the binding of classical benzodi-
azepines at their GABAAR binding sites (Costa and Guidotti,
1991). The endozepine diazepam-binding inhibitor (DBI) and
its metabolites were later shown to stimulate neurosteroidoge-
nesis after binding to TSPO (Papadopoulos et al., 1991; Do-
Rego et al., 1998). Few reports are available suggesting their
implication in pain. An antinociceptive effect of DBI on thermal
and mechanical thresholds has been reported after intrathecal or
i.c.v. infusion of DBI (Wang et al., 2002). In line, i.c.v. injection
of a bovine endozepine potentiated morphine analgesia in mice
(Chen et al., 1991). In apparent contradiction, the DBI-derived
ODN was shown to increase aggressive interactions in mice and,
surprisingly, to reduce defeat-induced analgesia (Kavaliers and
Hirst, 1986). In summary, these rare reports suggest a role for
endogenous TSPO ligands in the control of nociception. The
real expression levels of endogenous TSPO ligands, their cellular
localization and changes in pain pathologies are, however, still
largely unknown. This is in sharp contrast with TSPO expression
which has been found to be increased in several neuropathologies
including in pain models.
Beside TSPO ligands, we showed that oxytocin, a neu-
ropeptide released by hypothalamic neurons projecting onto
spinal nociceptive neurons, is exerting its long-lasting anal-
gesic effect by stimulating the production of AP (Juif et al.,
2013). Apart from its fast antinociceptive action in the spinal
cord which increases GABAergic inhibitory transmission and
reduces neuronal excitability (Breton et al., 2008, 2009), the
tonic activation of spinal oxytocin receptors in inflammatory
pain states also stimulates AP synthesis via ERK (for extra-
cellular signal-regulated kinase) signaling pathways, resulting
in the potentiation of GABAergic inhibition and limitation of
pain symptoms (Juif et al., 2013). It is not excluded at this
stage that other descending inhibitory controls may also exert
their antinociceptive action by modulating neurosteroid syn-
thesis, but this remains to be demonstrated. Another exam-
ple is related to substance P secretion by nociceptive primary
afferents which may inhibit the production of AP through its
NK1 receptor, as previously demonstrated (Patte-Mensah et al.,
2005). Taken into account this result, we may speculate the
diffuse AP-based analgesic system to be under the control of
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a balance of stimulating and inhibiting neuropeptides in the
spinal cord. This hypothesis requires to be tested in order to
identify the most promising peptides for future therapeutic
interventions.
CONCLUSIVE REMARKS
In conclusion, there are now several convergent experimental
evidences demonstrating that the local production of AP-like
steroids in the nociceptive system constitutes a diffuse analgesic
system. The development of numerous TSPO ligands capable of
stimulating this system is on the way, but little is known regarding
other possible physiological stimulators. In line with this idea,
neuropeptides could play a key role.
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